Kezar Life Sciences, Inc. (KZR)Healthcare | Biotechnology | South San Francisco, United States | NasdaqCM
7.33 USD
-0.04
(-0.543%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 7.33 Short-term: ★★★☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 1:14 p.m. EDT
KZR is currently trading near its 52-week high, with recent news about an acquisition deal and positive analyst ratings. However, the stock has a high overall risk and negative earnings, which raises concerns. The options data suggests mixed signals, with some bullish activity but also bearish positioning. While the stock may offer a short-term trading opportunity, the long-term fundamentals are weak, and the lack of dividends makes it unsuitable for dividend-focused investors. Overall, it's a high-risk stock with limited upside potential. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.077996 |
| AutoETS | 0.081371 |
| AutoARIMA | 0.082117 |
| MSTL | 0.083542 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 89.98 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.148 |
| Excess Kurtosis | -1.40 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.319 |
| Market Cap | 54,033,292 |
| Forward P/E | -2.75 |
| Beta | 0.43 |
| Website | https://www.kezarlifesciences.com |
As of April 11, 2026, 1:14 p.m. EDT: Options speculators are showing a mixed sentiment. The calls show some interest in the stock, with higher open interest and volume on the ATM strike at 7.5, indicating potential for a price increase. However, puts also show significant open interest on the 5.0 strike, suggesting some bearish sentiment or hedging against a potential decline. The IV is generally low, which could indicate a lack of conviction in either direction, but the presence of top OI on the higher strike suggests some bullish speculation.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.7759036 |
| Address1 | 4,000 Shoreline Court |
| Address2 | Suite 300 |
| All Time High | 363.3 |
| All Time Low | 3.53 |
| Ask | 7.37 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 122,470 |
| Average Daily Volume3 Month | 70,932 |
| Average Volume | 70,932 |
| Average Volume10Days | 122,470 |
| Beta | 0.431 |
| Bid | 7.3 |
| Bid Size | 1 |
| Board Risk | 9 |
| Book Value | 9.557 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.33 |
| Current Ratio | 11.52 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 7.39 |
| Day Low | 7.33 |
| Debt To Equity | 3.319 |
| Display Name | Kezar Life Sciences |
| Earnings Timestamp End | 1,778,616,000 |
| Earnings Timestamp Start | 1,778,616,000 |
| Ebitda | -51,373,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.296 |
| Enterprise Value | -15,223,846 |
| Eps Current Year | -4.02 |
| Eps Forward | -2.66667 |
| Eps Trailing Twelve Months | -7.66 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.833 |
| Fifty Day Average Change | 0.49699974 |
| Fifty Day Average Change Percent | 0.07273521 |
| Fifty Two Week Change Percent | 77.590355 |
| Fifty Two Week High | 7.55 |
| Fifty Two Week High Change | -0.22000027 |
| Fifty Two Week High Change Percent | -0.029139107 |
| Fifty Two Week Low | 3.53 |
| Fifty Two Week Low Change | 3.8 |
| Fifty Two Week Low Change Percent | 1.0764873 |
| Fifty Two Week Range | 3.53 - 7.55 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,529,587,800,000 |
| Float Shares | 5,158,447 |
| Forward Eps | -2.66667 |
| Forward P E | -2.7487464 |
| Free Cashflow | -29,152,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 9 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -33,756,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15816 |
| Held Percent Institutions | 0.60631 |
| Implied Shares Outstanding | 7,371,527 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,730,246,400 |
| Last Split Factor | 1:10 |
| Long Business Summary | Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. |
| Long Name | Kezar Life Sciences, Inc. |
| Market | us_market |
| Market Cap | 54,033,292 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_304157325 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -56,033,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 54,549,299 |
| Number Of Analyst Opinions | 2 |
| Open | 7.39 |
| Operating Cashflow | -51,777,000 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 650 822 5600 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 7.33 |
| Post Market Time | 1,776,456,605 |
| Previous Close | 7.37 |
| Price Eps Current Year | -1.8233831 |
| Price Hint | 2 |
| Price To Book | 0.7669771 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.226 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.03999996 |
| Regular Market Change Percent | -0.54274035 |
| Regular Market Day High | 7.39 |
| Regular Market Day Low | 7.33 |
| Regular Market Day Range | 7.33 - 7.39 |
| Regular Market Open | 7.39 |
| Regular Market Previous Close | 7.37 |
| Regular Market Price | 7.33 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 66,349 |
| Return On Assets | -0.29521 |
| Return On Equity | -0.59932 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 7,371,527 |
| Shares Percent Shares Out | 0.0273 |
| Shares Short | 201,330 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 176,056 |
| Short Name | Kezar Life Sciences, Inc. |
| Short Percent Of Float | 0.0279 |
| Short Ratio | 2.53 |
| Source Interval | 15 |
| State | CA |
| Symbol | KZR |
| Target High Price | 7.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 6.0 |
| Target Median Price | 6.0 |
| Total Cash | 71,878,000 |
| Total Cash Per Share | 9.751 |
| Total Debt | 2,326,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -7.66 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.5689 |
| Two Hundred Day Average Change | 1.7610998 |
| Two Hundred Day Average Change Percent | 0.31623834 |
| Type Disp | Equity |
| Volume | 66,349 |
| Website | https://www.kezarlifesciences.com |
| Zip | 94,080 |